OBJECTIVE

2

To provide suggestions and references for promoting the economic efficiency of anti-AIDS drug use in China.

METHODS

2

According to the

Chinese Guidelines for the Diagnosis and Treatment of AIDS

（2021

Edition

） and the

National Free HIV Antiretroviral Drug Treatment Manual

（4

th Edition

）， non-free anti-HIV drugs and therapeutic regimens were screened； the data on domestic and foreign drug prices were collected， and the price and affordability of non-free anti-HIV drugs and drug regimens were analyzed with the median price ratio （MPR） method and drug affordability study method by standard survey method.

RESULTS

2

A total of 18 non-free anti-HIV drugs （based on drug names） were screened， of which 5 drugs were only domestically produced， 11 were only imported， and 2 were both domestic and imported drugs； eight types were listed in the

Basic Medical Insurance Catalogue

（2021

Edition

）. The median MPR for 18 drugs was 0.504， and drugs with affordability of less than 1 accounted for 55% of the total number of drugs before medicare reimbursement， and thi

s figure increased to 75% after medicare reimbursement. The median affordability after reimbursement of 10 single-tablet combinations was 0.625， of which the affordability of the four single-tablet combinations recommended by the guidelines for use alone was less than 1. There was no statistically significant difference in the affordability of two regimens before and after medicare reimbursement and between recommended regimens and alternatives after reimbursement （

P

＞0.05）.

CONCLUSIONS

2

The affordability of single non-free anti-HIV drugs in China is good， but the affordability of combination drugs is poor. The affordability advantages of single-tablet combination formulations over conventional therapeutic regimens are significant. The government and enterprises should focus on the research and development of innovative drugs and strengthen drug price control， and establish and improve the non-free drug protection system for HIV/AIDS groups， so that they can choose more drugs and use drugs more economically.